Hubert Vesselle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11690496/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PET-CT image registration in the chest using free-form deformations. IEEE Transactions on Medical Imaging, 2003, 22, 120-128.	8.9	717
2	In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clinical Cancer Research, 2002, 8, 3315-23.	7.0	236
3	DNA Methylation in Tumor and Matched Normal Tissues from Non-Small Cell Lung Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 645-654.	2.5	157
4	Relationship Between Non-small Cell Lung Cancer FDG Uptake at PET, Tumor Histology, and Ki-67 Proliferation Index. Journal of Thoracic Oncology, 2008, 3, 971-978.	1.1	144
5	FLT: Measuring Tumor Cell Proliferation In Vivo With Positron Emission Tomography and 3′-Deoxy-3′-[18F]Fluorothymidine. Seminars in Nuclear Medicine, 2007, 37, 429-439.	4.6	139
6	Fluorodeoxyglucose Uptake of Primary Non-Small Cell Lung Cancer at Positron Emission Tomography: New Contrary Data on Prognostic Role. Clinical Cancer Research, 2007, 13, 3255-3263.	7.0	133
7	Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer. Journal of Nuclear Medicine, 2005, 46, 274-82.	5.0	108
8	The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2002, 124, 511-519.	0.8	86
9	Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies. Journal of Nuclear Medicine, 2005, 46, 371-80.	5.0	80
10	PET/CT scanner instrumentation, challenges, and solutions. Radiologic Clinics of North America, 2004, 42, 1017-1032.	1.8	65
11	DNA hypermethylation of tumors from non-small cell lung cancer (NSCLC) patients is associated with gender and histologic type. Lung Cancer, 2010, 69, 172-179.	2.0	60
12	18F-Fluorothymidine radiation dosimetry in human PET imaging studies. Journal of Nuclear Medicine, 2003, 44, 1482-8.	5.0	51
13	Relationship between Non-Small Cell Lung Cancer Fluorodeoxyglucose Uptake at Positron Emission Tomography and Surgical Stage with Relevance to Patient Prognosis. Clinical Cancer Research, 2004, 10, 4709-4716.	7.0	48
14	Tumor 3′-Deoxy-3′- ¹⁸ F-Fluorothymidine (¹⁸ F-FLT) Uptake by PET Correlates with Thymidine Kinase 1 Expression: Static and Kinetic Analysis of ¹⁸ F-FLT PET Studies in Lung Tumors. Journal of Nuclear Medicine, 2011, 52, 1181-1188.	5.0	48
15	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. European Journal of Cancer, 2019, 114, 107-116.	2.8	42
16	The Ki-67 Index and Survival in NonSmall Cell Lung Cancer. Cancer Journal (Sudbury, Mass), 2002, 8, 222-233.	2.0	37
17	Improved prediction of lobar perfusion contribution using technetium-99m–labeled macroaggregate of albumin single photonÂemission computed tomography/computed tomography withÂattenuation correction. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 2345-2352.	0.8	35
18	Thymidine Kinase 1 and Thymidine Phosphorylase Expression in Non-Small-cell Lung Carcinoma in Relation to Angiogenesis and Proliferation. Journal of Histochemistry and Cytochemistry, 2009, 57, 1087-1097.	2.5	26

HUBERT VESSELLE

#	Article	IF	CITATIONS
19	Overview of the Novel and Improved Pulmonary Ventilation-Perfusion Imaging Applications in the Era of SPECT/CT. American Journal of Roentgenology, 2016, 207, 1307-1315.	2.2	16
20	Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-[18F]fluorothymidine (18F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses. BMC Nuclear Medicine, 2007, 7, 3.	1.4	14
21	Evaluation of 5′-deoxy-5′-[F-18]fluorothymidine as a tracer of intracellular thymidine phosphorylase activity. Nuclear Medicine and Biology, 2007, 34, 471-478.	0.6	9
22	Functional Imaging Before Pulmonary Resection. Seminars in Thoracic and Cardiovascular Surgery, 2001, 13, 126-136.	0.6	8
23	Application of a neural network to improve nodal staging accuracy with 18F-FDG PET in non-small cell lung cancer. Journal of Nuclear Medicine, 2003, 44, 1918-26.	5.0	8
24	COVID-19 in an asymptomatic patient undergoing FDG PET/CT. Radiology Case Reports, 2020, 15, 1809-1812.	0.6	7
25	Synthesis and in Vitro Evaluation of 5-Fluoro-6-[(2-Iminopyrrolidin-1-YL)Methyl]Uracil, TPI(F): An Inhibitor of Human Thymidine Phosphorylase (TP). Nucleosides, Nucleotides and Nucleic Acids, 2010, 29, 49-54.	1.1	4
26	Nuclear medicine and the emergency department patient: an illustrative case-based approach. Radiologia Medica, 2015, 120, 158-170.	7.7	4
27	The Role of Pulmonary Scintigraphy in the Evaluation of Adults with Congenital Heart Disease. Seminars in Nuclear Medicine, 2017, 47, 660-670.	4.6	4
28	A simple quantitative assay for the activity of thymidine kinase 1 in solid tumors. Nuclear Medicine and Biology, 2007, 34, 619-623.	0.6	3
29	A SepPak unit for batch processing serial blood plasma samples for PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2007, 50, 679-682.	1.0	2
30	Multiple-Gated Acquisition Scan With Normal Left Ventricular Ejection Fraction and LBBB. Clinical Nuclear Medicine, 2014, 39, e410-e412.	1.3	2
31	Reply: Kinetic Analysis of ¹⁸ F-FLT PET in Lung Tumors. Journal of Nuclear Medicine, 2012, 53, 506.2-507.	5.0	1
32	Clinical Impact of FDG PET/CT of the Lower Extremities in Patients With Merkel Cell Carcinoma With Primary Disease Site Outside of the Lower Extremities. American Journal of Roentgenology, 2021, 216, 776-780.	2.2	1
33	Therapy-Induced Cellular Senescence. , 2008, , 295-306.		0